Matt Binnicker, Ph.D., Director of the Clinical Virology Laboratory in the Division of Clinical Microbiology at Mayo Clinic, recently presented on the Clinician Outreach and Communication Activity call, “Updated CDC Zika Laboratory Testing Guidance.”
In cases of sudden or unexpected death, autopsy evaluation can include a biochemical analysis to identify deaths caused by fatty acid oxidation disorders.
ST2 is a biomarker of fibrosis and cardiac remodeling and provides clinicians with significant prognostic guidance without being adversely influenced by typical confounders such as age, obesity, and renal impairment.
Two laboratories within the Mayo Clinic Division of Clinical Microbiology have joined efforts and launched a new service line dedicated to advancing the research and testing of vector-borne diseases.
Mayo Clinic will offer the Zika virus antibody test developed by the Centers for Disease Control and Prevention. This test has received Emergency Use Authorization from the U.S. Food and Drug Administration and has been licensed to select national reference laboratories, including Mayo Medical Laboratories.